Cargando…

Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial

BACKGROUND: Delayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-...

Descripción completa

Detalles Bibliográficos
Autores principales: Drobnic, Franchek, Riera, Joan, Appendino, Giovanni, Togni, Stefano, Franceschi, Federico, Valle, Xavier, Pons, Antoni, Tur, Josep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074833/
https://www.ncbi.nlm.nih.gov/pubmed/24982601
http://dx.doi.org/10.1186/1550-2783-11-31
_version_ 1782323255699308544
author Drobnic, Franchek
Riera, Joan
Appendino, Giovanni
Togni, Stefano
Franceschi, Federico
Valle, Xavier
Pons, Antoni
Tur, Josep
author_facet Drobnic, Franchek
Riera, Joan
Appendino, Giovanni
Togni, Stefano
Franceschi, Federico
Valle, Xavier
Pons, Antoni
Tur, Josep
author_sort Drobnic, Franchek
collection PubMed
description BACKGROUND: Delayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-investigated natural products, and is now commercially available as a lecithin delivery system (Meriva®, Indena SpA, Milan) with improved bio-availability. The aim of this study was to test whether curcumin could attenuate damage from oxidative stress and inflammation related to acute muscle injury induced by eccentric continuous exercise METHODS: This was a randomised, placebo-controlled, single-blind pilot trial. Twenty male healthy, moderately active volunteers were randomised to curcumin given as the Phytosome® delivery system 1 g twice daily (200 mg curcumin b.i.d.) or matching placebo. Supplementation was initiated 48 hours prior to a downhill running test and was continued for 24 hours after the test (4 days in total). Muscle damage was quantified by magnetic resonance imaging, laboratory tests and histological analyses on muscle samples obtained 48 hours after the test. Patient-reported pain intensity was also recorded. RESULTS: Subjects in the curcumin group reported less pain in the lower limb as compared with subjects in the placebo group, although significant differences were observed only for the right and left anterior thighs. Significantly fewer subjects in the curcumin group had MRI evidence of muscle injury in the posterior or medial compartment of both thighs. Increases in markers of muscle damage and inflammation tended to be lower in the curcumin group, but significant differences were only observed for interleukin-8 at 2 h after exercise. No differences in markers of oxidative stress and muscle histology were observed CONCLUSIONS: Curcumin has the potential for preventing DOMS, as suggested by its effects on pain intensity and muscle injury. Larger studies are needed to confirm these results and further clarify the mechanism of action of curcumin.
format Online
Article
Text
id pubmed-4074833
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40748332014-07-01 Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial Drobnic, Franchek Riera, Joan Appendino, Giovanni Togni, Stefano Franceschi, Federico Valle, Xavier Pons, Antoni Tur, Josep J Int Soc Sports Nutr Research Article BACKGROUND: Delayed onset muscle soreness (DOMS) due to eccentric muscle activity is associated with inflammatory responses and production of reactive oxygen species (ROS) that sustain both inflammation and oxidative stress. Curcumin, a powerful promoter of anti-oxidant response, is one of the best-investigated natural products, and is now commercially available as a lecithin delivery system (Meriva®, Indena SpA, Milan) with improved bio-availability. The aim of this study was to test whether curcumin could attenuate damage from oxidative stress and inflammation related to acute muscle injury induced by eccentric continuous exercise METHODS: This was a randomised, placebo-controlled, single-blind pilot trial. Twenty male healthy, moderately active volunteers were randomised to curcumin given as the Phytosome® delivery system 1 g twice daily (200 mg curcumin b.i.d.) or matching placebo. Supplementation was initiated 48 hours prior to a downhill running test and was continued for 24 hours after the test (4 days in total). Muscle damage was quantified by magnetic resonance imaging, laboratory tests and histological analyses on muscle samples obtained 48 hours after the test. Patient-reported pain intensity was also recorded. RESULTS: Subjects in the curcumin group reported less pain in the lower limb as compared with subjects in the placebo group, although significant differences were observed only for the right and left anterior thighs. Significantly fewer subjects in the curcumin group had MRI evidence of muscle injury in the posterior or medial compartment of both thighs. Increases in markers of muscle damage and inflammation tended to be lower in the curcumin group, but significant differences were only observed for interleukin-8 at 2 h after exercise. No differences in markers of oxidative stress and muscle histology were observed CONCLUSIONS: Curcumin has the potential for preventing DOMS, as suggested by its effects on pain intensity and muscle injury. Larger studies are needed to confirm these results and further clarify the mechanism of action of curcumin. BioMed Central 2014-06-18 /pmc/articles/PMC4074833/ /pubmed/24982601 http://dx.doi.org/10.1186/1550-2783-11-31 Text en Copyright © 2014 Drobnic et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Drobnic, Franchek
Riera, Joan
Appendino, Giovanni
Togni, Stefano
Franceschi, Federico
Valle, Xavier
Pons, Antoni
Tur, Josep
Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial
title Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial
title_full Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial
title_fullStr Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial
title_full_unstemmed Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial
title_short Reduction of delayed onset muscle soreness by a novel curcumin delivery system (Meriva®): a randomised, placebo-controlled trial
title_sort reduction of delayed onset muscle soreness by a novel curcumin delivery system (meriva®): a randomised, placebo-controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074833/
https://www.ncbi.nlm.nih.gov/pubmed/24982601
http://dx.doi.org/10.1186/1550-2783-11-31
work_keys_str_mv AT drobnicfranchek reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial
AT rierajoan reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial
AT appendinogiovanni reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial
AT tognistefano reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial
AT franceschifederico reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial
AT vallexavier reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial
AT ponsantoni reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial
AT turjosep reductionofdelayedonsetmusclesorenessbyanovelcurcumindeliverysystemmerivaarandomisedplacebocontrolledtrial